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Abstract 
The rapid development of biological defense mechanisms by bacteria, or antibiotic 
resistance, is a dangerously progressing public health concern worldwide. The spread of 
antibiotic resistant pathogens are not only a threat to the security of healthcare facilities and the 
stability of modern medicine across the globe, but this phenomenon also creates a particular 
burden on countries with a high prevalence of infectious disease such as India. This study 
attempts to explore India’s unique human healthcare causes of the emergence and spread of 
antibiotic resistance, comprehend the obstacles that have created roadblocks to change, and 
outline possible solutions to overcome these challenges. The study was conducted under the 
advisement of the New Delhi Center for Disease Dynamics, Economics, and Policy. The main field 
methods were observation and interviews with doctors, microbiologists, researchers, and public 
health workers in India; attendance at public lectures and medical conferences; and a review of 
secondary literature sources. The findings indicate that the causes of antibiotic resistance are 
multi-faceted, occur at all stages of healthcare delivery, and include the actions and attitudes of 
many stakeholders, including patients, medical professionals, pharmacists, and drug companies. 
Findings also detail possible challenges for implementing solutions, such as the absence of 
comprehensive data, a lack of awareness by the general public and medical communities, an 
overburdened health system fueled by a scarcity of resources, and delays in the innovation of 
diagnostic tools and alternative therapies. 
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Introduction 
 Evolution is the most powerful natural force; it has sculpted and melded every piece of 
life on this planet. In a race between man’s capacity to engineer modern medicine and the 
biological drive to survive and reproduce, evolution will always win out; one can’t outsmart the 
forces that shaped its own creation. Antimicrobial resistance (AMR) is the pinnacle of the 
competition between man’s inventions and evolutionary ingenuity, and it is this struggle which 
provides one of the most pressing global health crises of the 21st century.  
When Alexander Fleming identified penicillin in 1929, it was considered one of the 
greatest medical achievements in human history and was thought to be the end of death by 
infectious disease (Raghunath 2008). Although the development of antibiotics was a major 
victory in the treatment of communicable disease, it also prompted a biological “arms race” 
between microorganisms and medical technology (WHO 2014). The microorganisms of particular 
concern here are bacteria, as their increasing ability to survive even the most intense 
disinfectants and newest generations of antibiotics has been widely documented by global 
organizations such as the CDC and the WHO and constitute the largest potential threat to public 
health (CDC 2015). Almost all advanced procedures of modern medicine - from surgery to 
chemotherapy to basic sterilization - are extremely dependent on our supply of antimicrobials 
remaining effective. As one representative of the Indian Medical Research Council  explained in a 
lecture on AMR, a post-antibiotic world, in which pan-resistant microorganisms are everywhere 
and antibiotics are no longer effective, would threaten medical advances by “forcing us to 
recede to the dark ages, where people will die of simple infections and medical surgeries and 
procedures will be impossible to perform” due to an inability to disinfect tools, sanitize 
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healthcare facilities, or treat post-operative infection (Lecture Speaker 2, 17 November 2015). 
Identifying and controlling the factors which have contributed to the emergence and spread of 
AMR is a highest priority for the security of global health.   
Study Objectives 
The goal of the study was to explore the human healthcare causes of the spread and 
emergence of antibiotic resistance specific to India. It looks at the interventions currently being 
pursued in India and perceptions of obstacles to implementing these solutions by a few medical 
professionals, researchers, and public health workers. Although antimicrobial resistance 
encompasses a diversity of microorganisms, including viruses, fungi, and protozoa, this study 
primarily focuses on bacterial antibiotic resistance as this is estimated by the CDC to have the 
highest potential cost to public health, and is of particular concern in Indian healthcare. The 
study focuses specifically on human healthcare causes of AMR, and does not address in-depth 
agricultural or environmental factors. The study intends to understand the sources of this public 
health problem in an Indian-specific context, gain insight into practical obstacles from the 
perspectives of various experts, and seek knowledge about realistic and feasible steps to putting 
preventive measures in place. When discussing factors contributing to AMR, the study does not 
intend to associate blame with any of the mentioned stakeholders, nor does it mean to imply by 
its specificity that India is the only contributor to the problem. Resistance is a worldwide 
phenomenon, and many developed nations are far higher contributors to the global burden. 
Instead, it is believed by the researcher that India has high potential for being a global force for 
positive change in this area, and will hopefully only benefit from more information compiled and 
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awareness spread. Hopefully, this study will contribute a small piece of insight in order to pave 
the way for further, more extensive efforts.  
Research Questions 
The main question that the study seeks to answer is: what are the human healthcare 
causes of antibiotic-resistant infections in India and how can these problems be addressed? 
What practices in Indian healthcare facilities and pharmacies contribute to the emergence and 
spread of resistant bacteria? What promising research is currently being pursued by the 
government, public health organizations, and individual hospitals concerning AMR in India? Have 
any preventive measures been effective so far and, if so, how can these solutions be 
implemented on a larger scale? What are some of the cultural, economic, and political factors 
that create obstacles for implementing preventive measures and stewardship programs? 
  Field Methods 
Field methods include interviews, observation in hospitals and at CDDEP, scientific 
journal articles, one public lecture and panel discussion, “Rational Uses of Antibiotics” at AIIMS 
medical college and one medical conference “Antimicrobials: Access and Sustainable 
Effectiveness” at India Habitat Centre. The researcher collaborated with the New Delhi Center of 
Disease Dynamics, Economics, and Policies (CDDEP) and was advised by an infectious disease 
specialist and epidemiologist, Dr. Sumanth Gandra, who is a research fellow at CDDEP. Through 
this advising under CDDEP, the researcher was connected to Indian experts on AMR for  
interviews, had access to studies and research published by CDDEP, and was able to talk with 
and observe doctors and researchers studying AMR and global antibiotic usage. Nine individuals 
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were personally interviewed by the researcher either by phone or in-person, two of whom were 
interviewed on multiple occasions. Interviews were semi-structured, and therefore varied 
depending on the area of expertise and responses of the interviewee, but primarily asked for 
experiences with and opinions on India-specific causes, challenges, and promising solutions. As 
secondary sources were primarily used to obtain any statistical data, interviews were instead 
utilized to gain insight into the practical realities and experiences of those working in various 
aspects of healthcare that could not be obtained from literature review alone.  All interviewees 
were fully informed of the goals of the study and informed consent was obtained. Varying levels 
of identification are used for interviewees in respect for their wishes concerning anonymity.  
Background 
Antimicrobial resistance (AMR) is the process by which pathogenic microorganisms 
evolve defense mechanisms to become impervious to the medications which were once used to 
cure or prevent them (WHO 2015). Antibiotics work by two major approaches: either by killing 
the bacteria itself, or by inhibiting the cell’s reproduction (Aminov 2010). There are dozens of 
different types of antibiotics currently in use in the world today, all of which inhibit varying 
bacterial cell processes essential to its life or reproduction (Tenover 2006). Each category of 
antibiotic targets bacterial cells differently, and therefore, are specifically targeted and designed 
to treat only certain types of bacterial infections. When antibiotics are used, particularly when 
they are used unnecessarily or in the wrong dose or duration, it increases the selective pressure 
in a population of bacteria, causing vulnerable microorganisms to die and allowing the stronger, 
more evolved bacteria to survive and reproduce.  
M a t t e s o n  
I S P  | 9 
 
Bacteria are extremely well-adapted to quickly develop resistance. They multiply at 
astonishingly fast rates, can develop resistant strains through a single base pair mutation and are 
able to pass on resistant genes through a variety of unique mechanisms, such as horizontal gene 
transfer (Davies and Davies 2010). After the cycle of antimicrobial use and bacterial adaptation is 
completed a certain number of times, eventually the only bacterial population that remains is 
adapted to be completely impervious to the medicines attempting to target it (Tenover 2006). 
Antimicrobial-resistant microorganisms eventually stop responding to the classes of antibiotics 
that were once used to treat them. Corresponding infections become more difficult to treat, 
requiring costly or toxic drugs and more extensive care, and can possibly become incurable with 
any medication (Davies and Davies 2010).  
A certain amount of bacterial evolution is inevitable and natural  - it has been happening 
since the beginning of life itself (Lecture Speaker 1, 17 November 2015). Antibiotic resistance 
therefore has always existed, but has become a critical problem during the last 30 years, as the 
rate of the emergence and spread of resistant bacteria has obscenely accelerated due to 
antimicrobial misuses (WHO 2015). Without imprudent practices in human medicine, population 
dynamics would keep the proportion of resistant organisms low enough so it would not interfere 
with clinical outcomes (Lecture Speaker 1, 17 November 2015). However, misuse of 
antimicrobials has caused the evolutionary process of selective pressure to increase 
exponentially and, as a result, antibiotics continually become ineffective as resistant pathogenic 
microorganisms continue to spread and reproduce (Raghunath 2008; CDC 2015).  
The State and Burden of Antimicrobial  Resistance in India  
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  It may seem that in a healthcare infrastructure like India’s, which suffers from an 
imbalance of resources and a lack of financial support, that practices intended to control 
antibiotic misuse are extraneous or unnecessary. One doctor at a rural, public hospital shed light 
on this conflict of priority: “[Antibiotic resistance] is not something many doctors in India will 
recognize as an issue. With so many different problems [facing] patients and doctors in rural, 
[impoverished] areas, anything not immediate is put on the back burner. Doctors will say they 
don’t have time to confirm a diagnosis or the resources to run tests” (Interview 1, 14 October 
2015).   
First, it is essential to understand that, although the burden is often difficult to see in the 
short-term, antibiotic resistance carries profound and often devastating consequences. The 
progression of AMR is not something that merely harms individual patients or even individual 
hospitals. Resistant bacteria are exceptional at spreading and traveling at highly accelerated 
rates, through water supplies, food, and person-to-person transmission. Regional studies have 
been conducted over the last five years in India which reveal the alarming prevalence of these 
resistant bacteria. It is estimated that 95% of adults in India carry bacteria that are resistant to β-
lactam antibiotics (Shaikha 2015). β-lactam resistant enterobacteriaece has been reported in 70-
90% of Indian tertiary level hospitals (Ghafur et al. 2012). Research has revealed rapidly 
accelerating rates of Methicillin-resistant Staphylococcus aureus (MRSA) infections and last-
resort, Garbapenems-resistant klebsiella pneumonia in Indian healthcare facilities (Coghlan 
2015). Cases of entirely pan-resistant infections in tertiary-level hospitals and the widespread 
presence of antibiotic resistant bacteria in major city water supplies, such as New Delhi , have 
also been documented (Kumar et al. 2013). 
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The burden of resistant infections in India is deep and multi-faceted. Resistant infections 
can have double the mortality rate of their drug-susceptible counterparts. Methicillin-resistant 
Staphylococcus aureus (MRSA) infections, for example, kill at a rate 64% higher than susceptible 
staph (WHO 2015).  Resistance elongates the duration of illness and the intensity of care 
required so that AMR-resistant infections are able to spread to a larger number of people. Multi-
drug or pan-resistant infections are most likely to emerge and become epidemic in areas where 
infectious disease is widespread and sanitation is low (CDC 2015). Socioeconomically poor areas 
with high infection rates, such as urban slums, are most at risk for severe outbreaks of these 
dangerous infections as well as the least equipped to handle such a crisis and the most likely to 
have high mortality rates for nosocomial infections. Rural areas routinely fall victim to AMR 
infections, and unlike in urban areas, those affected are often not able to afford or access the 
best care or the newest generation of powerful antibiotics. The World Health Organization and 
the Center for Disease Control estimate at least 2 million deaths every year directly as a result of 
resistant infections (WHO 2015).  
The financial burdens of antibiotic misuse and resistant infections take a toll on every 
level of society. With over 600 million people living in poverty in India, the inappropriate use of 
antibiotics is a massive waste of scarce resources on expensive drugs that are not indicated or 
insufficiently dosed (Shrinivasan 2010; Saradamma et al. 2000). When a patient has a multidrug-
resistant infection, they require prolonged treatment with powerful, late-generation antibiotics 
which are often more costly and more dangerous, with serious side effects and a higher chance 
of mortality (Kumar et al. 2013). The intensive care and prolonged stay not only affect patient 
outcomes and quality of life, but also increase the cost of healthcare for both individuals and 
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country expenditure overall (Times of India 2014; Boucher 2009).  A nationwide analysis of the 
financial burden of resistance in India has not yet been published, but comparatively, the direct 
calculated annual burden of resistant infections in the UK is ₤1 billion and over $20 billion in the 
US (Plowman et al. 2001; APUA 2014).  
And that’s nothing compared to the threats that are slowly but surely emerging: the 
spread of antibiotic resistance has devastating, long-term consequences in hospitals and health 
centers. India is the first country to report resistance to colistin, a nephrotoxic and neurotoxic 
antibiotic reserved for only last-resort treatment. Colistin-resistant bacteria has been detected in 
Delhi hospitals at a rate of 4-5%, with corresponding infections often deemed as pan-resistant 
and untreatable (Shrivastava 2014). With the widespread presence of pan-resistant pathogens, 
hospital-acquired or post-operative infections can become deadly (CDC 2014). As the problem 
increases in severity, the safety of treatments such as organ transplants, cancer chemotherapy, 
or major surgery will be heavily compromised without effective antimicrobials to disinfect tools, 
sanitize operating rooms, or treat post-operative infections. According to a study by CDDEP, “up 
to half of infections after surgery and over a quarter of infections after chemotherapy are ca used 
by organisms already resistant to standard prophylactic antibiotics” (Teillant et al. 2015). CDDEP 
estimated that a “30% reduction in the efficacy of preventive antibiotics given routinely before, 
during, or after these procedures could result in 120,000 more infections and 6,300 infection-
related deaths every year” (Teillant et al. 2015). With nothing available to fight resistant 
pathogens, these microorganisms would rapidly spread to other hospitals, throughout the 
community, and across the country (Kumar et al. 2013). The major infectious diseases that we 
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have spent a century combatting would risk becoming uncontrollable and would derail India’s 
progress in reaching human health targets set by WHO and the UN.   
Enforcing stricter medicine protocols and implementing surveillance programs are not 
extraneous costs, but economically and medically responsible choices necessary for a sustainable 
future of medicine. Early prevention, especially in the form of antibiotic stewardship programs, is 
a relatively inexpensive option. Considering the severity of the consequences of inaction, 
particularly in overburdened, rural, or low-socioeconomic areas, this is a necessary step which 
could prevent the costly medical disaster of a post-antibiotic society in the near future (WHO 
2015).  
Causes of Antibiotic Resistance in India 
Role of the Pharmaceutical  Company 
For the first few decades after penicillin was discovered and mass-produced, 
pharmaceutical companies developed new antimicrobials with regularity, replacing them as 
frequently as their old brands became ineffective due to resistance. However, during the last 30 
years, as life spans have increased and chronic conditions like diabetes and heart disease have 
become the focus for medical innovation, big pharmaceutical companies have brought the 
research and development of new antimicrobials, particularly gram-negative antibiotics, to a 
startlingly halt (Boucher et al. 2009). No new classes of antibiotics have been discovered and 
produced since 1987 (Knapton 2015). One epidemiologist explained this change as follows: “For 
pharmaceutical companies there is simply not enough return on their investment to continue to 
develop new antimicrobials. They are only taken by a patient for a short, temporary period, 
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bacterial infections are curable, and after a while they become ineffective due to the 
development of resistance” (Interview 4, 1 December 2015).  
One particularly harmful trend in Indian pharmaceuticals is the production of fixed-
combination antibiotics (FDCs), where two or more antibiotics are combined and administered 
as one pill (CDMU 2010). For pharmaceutical companies, these combinations are an easy way to 
sell two medicines when one (or even none) may be needed for the patient, significantly 
increasing profits (Gautum and Saha 2008). According to one microbiologist interviewed, many 
of these fixed-combination antibiotics are irrational combinations, with little to no evidence 
indicating their effectiveness (Interview 9, 4 December 2015). Literature suggests that many 
FDCs can have toxic effects, have a higher risk of adverse drug effects, and contribute to the 
occurrence and severity of in-patient antibiotic-resistant infections (Hirsch et al. 1960). More 
than 100 drug combinations which are not approved in any developed country are currently 
being marketed in India (CDMU 2010). Despite the overwhelming evidence that most brands are 
unnecessary or even harmful, fixed-dose combination antibiotics are still widely administered for 
surgical prophylaxis and in basic antimicrobial therapies (Gautum and Saha 2008).  
Role of the Medical  Prescr iber  
 In sheer volume, India is the highest consumer of antibiotics in the world, with 12.9 
billion units being consumed in 2010 alone (Ganguly 2011). The use of antibiotics in India 
doubled in the five years between 2006 and 2011, with a particular increase in sales of new-
generation, powerful antibiotics such as carbapenems, linezolid, daptomycin, and tigecyclin,  
which are intended to be reserved as clinical last-resorts to the most severely virulent and 
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resistant infections (DNA 2011; Ganguly 2011). What is distressing about these high rates of drug 
consumption is that instead of being indicative of expanded access to medicine, most increases 
in the sale of antibiotics are for conditions that are not treated by them, such as viral or fungal 
infections. One doctor from the All India Institute of Medical Sciences (AIIMS) explained, “As high 
as 50% of antibiotics are used for something that is not treated by antimicrobials. In many 
hospitals and practices in India, antibiotics are routinely prescribed for every fever, cough, or 
diarrhea case, even when there is no indication of a bacterial infection” (Lecture Speaker 2, 17 
November 2015). In regional studies, depending on the area, 45 to 80% of patients with 
symptoms of acute respiratory infections and diarrhea were given an antibiotic, even though 
these are more commonly attributable to viral infections for which these medicines are 
ineffective (Kumar et al. 2008). 
 Over-prescription and misuse have deep roots which extend in many different directions. 
First, it begins with a lack of knowledge about the role of antimicrobials and a misperception of 
antibiotics as an inexhaustible resource, by both medical professionals and lay people. According 
to one hospital director, “In India, patients - even doctors sometimes - assume that antibiotics 
are pills that cure everything. They will take them immediately when they start to get sick, 
whether or not they [have a bacterial infection]” (Interview 2, 16 October 2015).  In a 2015 study 
of patient perceptions, a large proportion of individuals assumed that any time they felt 
particularly ill or had been sick longer than they expected to be, antibiotics would help 
(Wellcome Trust 2015). The majority of individuals surveyed had never heard of antimicrobial 
resistance, were skeptical of the concept when it was explained to them, and didn’t believe their 
use of antibiotics was excessive. Misconceptions often lead to patients either demanding 
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antibiotics from practitioners and switching doctors if they don’t receive them or going to a 
pharmacist to obtain medication without consultation (Wellcome Trust 2015).   
Second, it is essential to consider the context of the healthcare setting in India. The 
healthcare system is notoriously overburdened and underfunded in India, with a doctor to 
person ratio of 1:1700 and a staggeringly low 1.3% of the GDP expenditure spent on public 
health (Biswas 2014; World Bank 2015). One specialist described, “In Indian hospitals, infectious 
diseases are extremely common and create a huge burden on the system. It takes longer to 
explain to a patient the difference between viral and bacterial infection and why you’re not 
prescribing them medicine than to just write a prescription. When you’re seeing hundreds of 
patients a day, it’s impossible to run tests and spend half an hour with everyone who comes in 
with a fever” (Interview 5, 23 November 2015).  
 Third, in many areas there is not only a lack of time, but a lack of resources. According to 
WHO recommended guidelines, except in the case of emergency interventions, antibiotics 
should not be prescribed for a patient until a bacterial infection is confirmed by cultures or blood 
tests. But to properly run bacterial cultures requires access to a microbiological lab, biological 
testing equipment, staff who are trained in the procedure, and money to fund the testing. In 
rural areas, there may be little to no access to such facilities or personnel. Outside of major 
cities, doctors often do not have access to the tests or lab needed to confirm a diagnosis of 
bacterial infections when ambiguous symptoms such as fever, sore throat, or diarrhea occur  
(Easton 2011). This leads to the use of “shotgun therapy”: a person may or may not have a 
bacterial infection, so a doctor just prescribes an antibiotic anyway.  
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The lack of rapid diagnostic tests for bacterial infections is also a deterrent to testing. “If a 
patient is feeling sick and has travelled far or missed work to see a doctor, they don’t want to 
wait around for diagnostic testing to be done to confirm that they have a bacterial infection,” 
explains one physician (Interview 4, 12 November 2015). “They just want to be given medicine, 
even if it won’t help them or will make them sicker.”  
Role of the Patient 
In large cities of India, like Mumbai, New Delhi, and Chennai, there is an epidemic of 
patient self-prescribing. Despite laws passed in 2011 to regulate antibiotics obtained without a 
prescription, it has been widely documented that, particularly in urban areas, antimicrobial 
agents are “readily available and can be purchased as a commodity without the advice or 
prescription of a physician or other trained health care provider” (Knobler 2003). A 2011 analysis 
by the Global Antibiotic Resistance Partnership (GARP) and the Public Health Foundation of India 
(PHFI) found that one-fifth of the antibiotics purchased recently in Delhi had been obtained 
without a prescription (Ganguly 2011). In various regional studies of Indian pharmacies, 
depending on the area, estimates range from 42-64% of antibiotics obtained without 
consultation with a doctor (Saradamma 2000).  
When patients self-prescribe without medical consultation, they often take antibiotics 
when unnecessary, not finish the complete course, purchase the wrong type, or take an 
insufficient dose. A study of Delhi pharmacies found that 90% of antibiotic purchases were an 
incomplete dose, and the median number of pills purchased was three (Kotwani et al. 2012).  
Lack of adherence to the full course of antibiotics is a common and dangerous practice. Patients 
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will often stop taking medicine after the first few days, once they start feeling better. As a result, 
the bacteria causing the illness are not fully killed, and this breeds conditions for resistant 
bacteria to reproduce (Chan et al 2012). In some areas, these problems of noncompliance and 
self-medication are magnified because in developing countries, “significant amounts of the 
available antimicrobials are poorly manufactured, counterfeit, or have exceeded their effective 
lifetimes” (Knobler et al 2003). 
Role of the Pharmacist 
The policies and education of pharmacists encourage the proliferation of inappropriate 
antibiotic consumption and enable self-medicating practices. According to one doctor at a 
private hospital, “The pharmacist plays a huge role in emerging resistance. They make money by 
selling as much medicine as possible and antibiotics are an easy drug to dispense unnecessarily” 
(Interview 7, 28 November 2015).  Economic forces favor the growth of small drug shops in 
urban areas which compete for business and are enticed by the incentives of pharmaceutical 
companies to push their products for substantial compensation (Kamat and Nichter, 1998). 
These incentives encourage pharmacists to sell the newest brand-name medications while the 
drug patent is still valid, in order to turn over as large a profit as possible. 
Speaking at a medical conference, one pharmacist and microbiologist attributed difficulties 
to the fact that “pharmacy practices and chemist shops in India are not held to high standards of 
regulation” and emphasized that education of most people working at a chemist shop is often 
“none or minimal” (Conference Speaker 1, 30 November 2015). Currently, there is no strict 
regulatory body or control for clinical pharmacy practice in India (Basak and Sathyanarayana 
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2010).  To practice as a registered pharmacist, only a diploma in pharmacy is required, taking a 
little over two years, after which no further education or certification is needed. Many 
pharmacies operate without a registered pharmacist even employed (Basak and Sathyanarayana 
2010). In a 2005 study of Indian pharmacies, 50% were found to function without a pharmacist 
on site, with the store owner or a relative dispensing drugs without any formal training (Basak 
2009).  
Obstacles and Solutions 
Strategies to tackle the emergence and spread of antibiotic resistance in India focus primarily 
on one of three areas: preventing and slowing the emergence of resistant bacterial genes, 
containing the spread of resistant pathogens, and producing innovations in diagnostics, 
monitoring, and alternative therapies. The following section overviews gaps in essential AMR 
knowledge, outlines some of the efforts that are currently being explored, describes possible 
solutions yet to be attempted, discusses the unique obstacles to implementation, and suggests 
routes for future research.  
Survei l lance of AMR  
An unavoidable part of the problem is that in many areas we don’t have a thorough 
understanding of what the problem is. In a lecture on AMR and nosocomial infections, one 
medical researcher explained, “Most of the data [that] scientists have on the prevalence of drug- 
resistant infections was compiled in Western countries. We need to truly define the burden of 
infection in India in order to implement preventive measures, starting with surveillance that 
measures compliance as well as treatments, the type of antibiotics given, and the dosage” 
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(Lecture Speaker 3, 17 November 2015). In India, a huge obstacle to overcome is that “large 
parts of country do not have the technical infrastructure to generate useable data” about the 
prevalence of AMR infections (Raghunath 2008).  
Strides have been made in surveillance during the last 5 years. The New Delhi CDDEP has 
processed and organized global data on the status of global antibiotic usage into a 2014 report 
and currently receives resistance data from routine microbiological testing of bacterial 
susceptibility to antibiotics from six different labs in various regions of India. An updated map of 
global antibiotic usage data and resistance data is available to the public on the CDDEP website 
(CDDEP 2015). The Indian Council of Medical Research (ICMR) has also taken a proactive 
approach to AMR surveillance. According to one ICMR researcher, “For the last two years, we 
have received data on bacterial resistance at four centers across India. We are hoping to add 
another ten centers of data collection in the next few years” (Conference Speaker 2, 30 
November 2015).  
Although this is an important contribution to our knowledge of the state and spread of 
resistance, it is also slightly skewed in representation, as data in India is collected primarily on a 
volunteer basis from urban hospitals with infection control programs already in place. State 
policies which require hospitals to collect and submit clinical and microbiological data about 
resistant and hospital-acquired infections could increase our understanding of the problem in 
rural and low-socioeconomic settings and may stimulate infection control measures.   
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Publ ic Awareness 
Many experts interviewed emphasized the need for efforts to “increase public awareness of 
AMR through health campaigns and the media” (Interview 8, 1 December 2015). Initiatives to 
educate patients have the potential to increase understanding, improve rates of medication 
adherence, and deter self-medicating trends. Studies show that patients who have a basic 
understanding of antibiotics are much less likely to abuse them or request them unnecessarily 
from medical prescribers (FiIipetto 2008).  
There are promising indicators of the potential for education and public awareness 
campaigns on topics of antibiotics, drug resistance, and vaccination to effectively spread the 
message, particularly in urban populations. For one, health awareness campaigns have been 
underway in India for several years, and therefore can provide a model to build off of and learn 
from. Some have even been fairly successful, with Indian health communication campaigns on 
diseases such as leprosy, maternal health, and HIV/AIDS linked to health-proactive behavioral 
changes (Sood and Nambiar 2006).  Three of the practicing doctors interviewed emphasized the 
country’s traditionally strong family and community presence in the care of those who are sick as 
a powerful force for positive change. When you pass memorable health knowledge on to one 
person in India, “you are likely also benefitting many others who are their family, friends, and 
neighbors” (Interview 7, 28 November 2015). According to one doctor, campaigns should be 
kept short, use a widely-viewed form of media such as television, and have a simple message 
that can be easily remembered (Interview 9, 4 December 2015). Small messages such as “not 
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every cold needs antibiotics” or “sharing antibiotics can do more harm than good” can spread 
widely and create a large impact. 
Balancing National  Contradictions in Access  to Medicine 
Considering how widely they are misused and the high resulting potential for harm, it may 
seem at first that strict bans on the distribution of antimicrobials outside of hospitals are a 
simple solution. However, while overuse of antibiotics is a huge problem in urban and affluent 
areas of India, in rural areas, villagers suffer from a lack of access to any form of healthcare. For 
many, the cost of visiting a doctor is simply too high. For others, healthcare may be free or 
subsidized, but the quality of this care is severely lacking. Villagers may not have a hospital within 
a reasonable distance from their homes, or reliable transportation to get there. This diversity in 
the socioeconomics and culture of different regions in India is one of the main barriers in 
creating universal policies for the promotion of rational uses of antibiotics. A national policy 
which limits access to antibiotics without a prescription may be immensely helpful for 
combatting AMR in higher-income, urban areas, but for a rural villager, the idea of obtaining a 
prescription from a qualified physician may serve only as a further barrier to care. Proactivity in 
AMR policies is essential to preserve the resource of antibiotics, but it must be carefully balanced 
with consideration of the fact that “many individuals still die in rural areas from preventable and 
easily treatable infections due to a lack of access to life-saving drugs” (Conference Speaker 3, 30 
November 2015). 
The Chennai Declaration addresses these concerns through their idea of an “implementable 
antibiotic policy” instead of a “perfect policy” (Ghafur et al. 2013). The Chennai Declaration was 
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a document composed and published in 2013 by representatives from a variety of Indian medical 
societies describing the ideal steps for tackling AMR over the next five years. The document 
acknowledges that enforcing universal restrictions may not be immediately feasible, and that it is 
more realistic on certain issues to implement step-by-step changes over time and in a way that is 
sensitive to economic and political context (Ghafur et al. 2013). One viable route for regulating 
the sales of antibiotics is to begin by implementing stricter controls in large, urban cities, where 
access to a licensed physician is not as insurmountable a problem, and where the highest 
incidence of antibiotic misuse and the biggest contribution to AMR is occurring. In rural, low-
socioeconomic areas, regulations on new-generation, last-line of defense antibiotics may be put 
in place, as treatment of a multi-drug resistant infection would require a doctor’s consultation or 
hospitalization either way, but regulations on basic antibiotics needed to treat minor infections 
would be held off. In rural areas, a push to educate doctors on AMR, increase access to 
healthcare, improve community and hospital sanitation, and increase vaccination rates should be 
more immediate priorities which will both increase community health and indirectly decrease 
the antibiotic misuse and AMR progression.  
Improve Hospital  and Community Sanitation 
One way to both contain the spread of resistant pathogens and decrease the incidence of 
infection entirely is by improving sanitation in healthcare facilities. Studies by the Global 
Antibiotic Resistance Partnership (GARP) have revealed extremely high rates of hospital-acquired 
and resistant infections in many Indian hospitals and health centers. In certain ICUs, the rate of 
vancomycin-resistant enterococcus, a dangerous hospital infection, is five times the rate in the 
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rest of the world (India Medical Times 2011). Over 80% of samples taken in one hospital-based 
study found Staphylococcus aureus bacteria that was resistant to methicillin and other related 
antibiotics. GARP estimates that 30% of the 190,000 neonatal deaths in India each year due to 
sepsis are attributable to antibiotic resistant bacteria in hospital environments (India Medical 
Times 2011). 
Director of CDDEP and vice president for research and policy at the Public Health 
Foundation of India, Dr. Ramanan Laxminarayan, explains in an article on nosocomial infections 
that most of these infections are easily preventable with simple measures, such as “frequent 
hand washing, use of isolation rooms for infected patients, increased availability and uptake of 
diagnostic tests, reminders to limit catheter use, and use of gloves and gowns” (India Medical 
Times 2011). Establishing infection control and stewardship committees which review 
prescription records and oversee hospital sanitation can be a big step to ensure sincere 
compliance and create accountability for following policies. However, these committees may 
also be met with uncooperative hospital staff and administrators. “The greatest challenge is to 
empower infection control committees and make hospital staff aware of their activities and 
recommendations,” adds Dr Ramanan Laxminarayan (India Medical Times 2011). 
When the researcher completed a brief observership at a private hospital, it was noted 
that hundreds of patients were seen by the doctors in only a few hours, with multiple patients 
often being examined and diagnosed in the same room at the same time. Even at this private 
hospital, no sterilization of equipment or the room, use of gloves, or handwashing between 
patients was observed on the part of the doctors or nurses despite the fact that many of the 
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cases were contagious infections such as tuberculosis or pneumonia. These practices are also 
consistent with the researcher’s brief observations of hygiene practices in several other hospitals 
and health centers in Rajasthan, Delhi, and Uttar Pradesh.  
Hospital sanitation is perhaps the most perplexing contradiction of India’s healthcare 
system. While India is definitely home to many top private hospitals with excellent infection 
control procedures, a huge number are still falling short in basic sanitary practices, even when 
they have adequate resources and a well-trained staff. When discussing the odd contradiction of 
well-educated and skilled medical professionals failing to consistently adhere to basic hygiene 
measures such as hand-washing and glove use, many of the experts interviewed referred to the 
mental disconnect between associating these small hygiene tasks with the resulting adverse 
outcomes. Educational and stewardship efforts may benefit from not only focusing on teaching 
hygiene guidelines, but also providing memorable evidence and imagery that truly connect the 
harm of dangerous infections with seemingly small lapses in infection control. In addition, 
developing national standard treatment and “infection control guidelines outside of those 
required for NABH accreditation” with a focus on resource-strapped and rural areas may provide 
more feasible targets for hospitals still struggling with these changes (Conference Speaker 2, 30 
November 2015). 
Creative solutions can also be used to motivate and implement infection control practices 
on the hospital level in resource-limited areas. At the Comprehensive Rural Health Project’s Julia 
Hospital in Jamkhed, Maharashtra, they address the challenge of hospital sanitation in a rural, 
resource-limited community in an original but simple way. According to their model, “80% of 
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health problems can be prevented or managed” by laypeople, even in impoverished or illiterate 
communities (CRHP 2012). Therefore, when patients stay for prolonged periods in their hospital, 
the staff teaches the patient and his/ her family how to do basic tasks like changing the patient’s 
sheets, washing hands, and monitoring medication compliance. This approach has many 
benefits, explains the hospital’s director: “Involving the families in patient care lowers the 
required manpower and healthcare costs, empowers the patient and their family, and teaches 
valuable hygiene and health skills to villagers who will then often share them with thei r 
communities after they leave the hospital” (Interview 2, 16 October 2015).  As a result of this 
method, healthcare costs are extremely low at Julia Hospital, and according to the director, 
there “has never been a case of hospital-acquired infection in over 40 years since it was 
founded” (Interview 2, 16 October 2015).  
AIIMS Hospital’s Trauma Center has been testing a software, ASHAIN, which monitors 
infection control procedures, medical devices, and the duration and dosage of antibiotics. 
Studies have found that use of ASHAIN helps to reduce infection rates by up to 50% merely by 
creating a system of accountability and surveillance (Bhalla 2012). In addition, use of the 
software makes it easier for subtle infection trends to be tracked and monitored, so the source 
of the infection can be eliminated, rather than merely continuing to treat the aftermath. The 
widespread implementation of infection control software could be a useful and low-cost tool for 
combatting nosocomial infections and irrational antibiotic use (Bhalla 2012).  
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Antimicrobial  Stewardship 
As an addition to standard infection control teams, in a recent years, a few major 
hospitals in India have begun piloting antimicrobial stewardship programs which specifically 
target the incidence of resistant infections, address poor diagnostic practices, and encourage the 
optimal use of antimicrobials (ASBN 2013). These antimicrobial stewardship teams work by 
creating a network of cooperation, implementing a team which oversees routine monitoring and 
surveillance of prescribing policies, pharmacy operations, and patient and prescriber education 
(ASBN 2013). They also may assist busy practitioners in accessing the proper antibiotic type, 
dose, and duration for cases of infection and provide informational resources for staff and 
medical professionals.  
Apollo Hospital in Chennai was one of the first Indian hospitals to successfully implement 
such a program in their tertiary level oncology center. A study was conducted to analyze the 
impact of antibiotic stewardship activities- such as handwashing monitoring, strict isolation 
procedures for immunocompromised patients, AMR education for junior medical practitioners, 
infection protocol education for patient families and visitors, and consultation with an infection 
control committee- on the prevalence of carbapenem-resistant Enterobacteriaceae. The study 
found a significant decrease in the use of higher level antibiotics and in the prevalence of three 
different strains of resistant bacteria in only two years (Ghafur et al. 2012). Explains one 
specialist: “The effectiveness of the Chennai program, especially considering that it was 
conducted in an oncology ward, where patients are at high risk for severe infections, means that 
these policies are very capable of being implemented in other hospitals in India. What really 
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makes a difference is the level of education of the staff about antimicrobial resistance and the 
cooperation of the hospital community” (Interview 5. 23 November 2015).  
One of the private hospitals that the researcher visited also had a strong, independent 
antibiotic stewardship program. Their program was headed by a review board, led by a physician 
who was interested in antimicrobial conservation. The review board oversaw the hospital’s 
antimicrobial prescriptions and advocated for awareness and rational use. The program placed a 
hospital ban on the use of irrational drug combinations and restrictions on certain high-end, last 
resort antibiotics, which required consultation and sign off by another doctor. The program also 
made information on infectious strains and corresponding antibiotics readily available to all 
doctors and encouraged the recording of infection data and monitoring of patients on more than 
two antibiotics.  
Over the last two years, the Antibiotic Stewardship Network in India, based in Ujjain, 
Madhya Pradesh, has begun setting up a network of Indian healthcare workers dedicated to 
AMR accountability throughout the country and offering informational classes on AMR 
stewardship (ABSN 2013). National programs to connect representatives from different hospitals 
have the benefit of being able to collaborate data on a large scale, implement widespread 
accountability, and share resources and innovation.  
Diagnostics 
Improvements in diagnostics have the potential to create a large, sustainable change in 
antimicrobial resistance. Currently, clinicians generally prescribe antibiotics empirically; when a 
patient comes in with symptoms of infection such as fever, cough, or diarrhea, clinicians will 
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prescribe a broad spectrum antibiotic without running any diagnostic tests (Murdoch et al. 
2012). This practice has the benefits of saving time, but it is often inappropriate and ineffective, 
resulting in unnecessary or pathogen non-specific treatment (Braykov and Laxminarayan 2014). 
When asked about empiric prescribing, medical professionals commonly cite a lack of time or 
testing resources to run diagnostic tests, and pressure to be completely certain of results before 
turning a patient away without a prescription.  
Unfortunately, many of the symptoms of bacterial and viral infections are identical, and no 
highly sensitive, universal clinical prediction rules for distinguishing the etiology of the infection 
currently exist (Murdoch et al. 2012). Classic tests for determining the pathogenic strain of 
infection include bacterial cultures, susceptibility tests, gram stains, blood tests, PCR, and 
enzyme-linked immunosorbent assay (ELISA). However, testing is not quick enough to be 
clinically useful, with the standard process of culture and susceptibility testing generally takes 
24-48 hours (Maltezou 2008).  
One possibility is the development of rapid diagnostic tests to identify infectious pathogens 
right at the point of care. A two-year study on the effects of a rapid antigen detection test 
(RADT), which can identify certain bacterial strains and their level of susceptibility, on antibiotic 
prescribing found that antibiotic prescription was reduced by 61% using the RADT compared 
with typical empirical management of patients (Maltezou 2008). A 2011 study in Israel 
developed a chemiluminescence-based blood test which distinguished between viral and 
bacterial infection in blood samples in less than two hours and with over 90% accuracy (Prilutsky 
et al. 2011).  
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Rapid, point-of-care diagnostic tests for viral and bacterial pathogens have the potential to 
improve the quality of infection care and decrease the spread of resistance and are worthy of 
priority in medical development and research. However, it is also important to acknowledge the 
practical limitations of these tests. First, although the last five years have brought promising 
innovations in quick and effective tests, all rapid diagnostic tests currently on the market or in 
development have limitations in their accuracy (Maltezou 2008). Even if a rapid diagnostic test is 
90% accurate, the slight chance it is wrong still creates a liability for the doctor and therefore 
hesitation to rely on the test’s results. Second, antibiotics in India are widely available and 
extremely inexpensive. According to one doctor, “In order for a rapid diagnostic test to be useful 
in India, it would have to be not only fast and accurate, but also less expensive than generic 
antibiotics” (Interview 4, 24 November 2015). The reality is that most patients do not want to 
pay for a test when they can just receive a treatment.  Finally, many of the practicing doctors 
interviewed mentioned that medical professionals are “habituated to their diagnostic methods” 
(Interview 7, 28 November 2015). For a physician to change their practicing methods after 
decades without feeling confident in the reliability, expense, or usefulness of the test would be 
an unrealistic request for many. In order to prompt medical professionals to make a substantial 
change in their practice, the proper tools, resources, and motivation need to be provided to 
make that transition as smooth as possible.   
For areas where rapid diagnostic tests are not available, a more feasible first step may be to 
improve empirical diagnostic and prescribing practices. In a study by CDDEP of empiric methods 
in hospitals, a third of patients receiving antimicrobial medications had no symptoms or tests 
which indicated an infection. Few patients had diagnostic tests conducted to determine the 
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source of infection tests. For those who did and had the tests show up as negative for bacterial 
infection, only 22 percent had their medication stopped or the spectrum narrowed (Braykov and 
Laxminarayan 2014). Even where rapid diagnostic tests are not readily available, doctors should 
be encouraged to narrow broad-spectrum treatment when an infection is identified or cease 
antibiotic administration upon negative test results. Appropriate antimicrobial de-escalation is an 
important component of antimicrobial stewardship which can minimize overuse in in-patient 
care. 
Attitude and Pr ior ity 
In discussing AMR with doctors and researchers, one step that was mentioned almost 
universally was the need for an attitude change regarding antibiotics and resistance by doctors, 
the government, and the general public. “To make any change in medicine,” explains one doctor 
and researcher, “it requires first a change in attitude and a sense of cooperation. You can instill 
and enforce policies, you can improve access to [the required tools], and you can secure proper 
funding, but if doctors and patients don’t view resistance as important, the problem will 
continue to get worse.” (Speaker 5, November 23). This prompts the question at the base of all 
AMR interventions: how do we motivate stakeholders to authentically change imprudent 
practices? 
Large, private hospitals in major cities are prompted to strive for strictly enforced 
stewardship practices and infection control programs in order to achieve hospital accreditation, 
maintain a good reputation, and secure funding. A regulatory committee that oversees 
prescriptions is a mandatory requirement for any hospital seeking accreditation from the 
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National Accreditation Board for Hospitals & Healthcare (NABH) (IBNS 2015). Accreditation and a 
good reputation are valued in order to encourage patients to choose their hospital for medical 
tourism and surgical procedures, which are huge income-generators for many large, private, 
urban hospitals. For these hospitals, a further step toward accountability may be a state 
requirement for them to publicly release annual data on resistance, nosocomial infections, and 
antibiotic prescriptions.  
These motivators, however, do not apply to rural Community Health Centers (CHCs) and 
government-funded district hospitals, where it can be a challenge to prompt them to notice or 
admit to a problem, let alone voluntarily submit data about hospital-acquired or resistant 
infections or implement preventive measures. Government-funded hospitals and CHCs present a 
challenge, as they have no obvious incentive to track or release data about their burden of AMR 
or enforce stringent infection control procedures. When asked how to motivate rural district 
hospitals to promote AMR stewardship, one medical researcher explained, “It has to start with 
private hospitals and move down. Recently, a few private hospitals in India like AIIMS have 
implemented infection control and stewardship programs, and have published research. The 
more attention [is drawn to the problem,] the more the Health Ministry will regard resistance as 
a priority and state governments may require district hospitals to implement programs to 
receive funding” (Interview 6, 24 November 2015).  
Additionally, now that research exists which shows how cost-effective antimicrobial 
stewardship is for hospitals, it creates an incentive for hospital administrators to develop plans 
and enforce these policies. According to a doctor with the Indian Institute of Health 
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Management Research (IIHMR), around 50% of patients in India fail to take medicines properly 
(Speaker 2; IBNS 2015). Pharmaceutical management in hospitals can be one of the most cost 
effective measures for appropriate use of scarce health care resources, making it a desirable 
course to pursue for hospital administrators and state governments. Medication management 
through a functional Drug and Therapeutics Committee (DTC) can provide a place for 
cooperative efforts to promote more efficient and rational medicine use. 
China has implemented a promising stewardship and drug regulation reform during the 
last nine years which has been shown to significantly reduce antibiotic over-prescribing and cut 
excessive retail sales of antimicrobials (Xiao et al. 2013). The Chinese Ministry of Health has 
introduced mandatory policy changes in gradual steps for the conservation of antimicrobials, 
setting targets for antimicrobial conservation, organizing task forces and supervisory drug 
committees, developing strict inspections, and investigating hospital management staff who 
continue to violate conservation policies. Policies placed the responsibility of overuse on hospital 
staff and medical prescribers; hospitals that failed to meet targets could be downgraded to a 
lower level, and medical staff who seriously violate the regulations could lose their accreditation 
to prescribe antibacterial agents or have their professional qualification revoked. China’s 
Ministry of Health also attempted to implement changes in the next generation of physicians, 
holding national medical education programs on the appropriate use of antibiotics (Xiao et al. 
2013). If such a program were attempted in India, changes would have to be made to adjust for 
cultural and political differences, but China’s policies suggest the role of assignment of 
responsibility and strict enforcement to motivate substantial behavioral changes in healthcare.  
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Changes in Medical  Education 
 A long-term step in tackling AMR is to emphasize positive infection control practices, 
diagnostic methods, and rational antibiotic use in the education of the next generation of 
pharmacists and medical professionals. Three physicians I talked with mentioned as a 
contributing roadblock that medical and pharmacological schools did not incorporate 
mechanisms of antimicrobial resistance, evaluations of the rationality of drug combinations, or 
extensive infection control discussions into the curriculum (Interviews 2, 4, and 7, November 
2015). The Chennai Declaration recommends specific changes in medical education, including  
offering Post-MD/DNB specialization in infectious diseases at more post-graduate centers, 
requiring compulsory training in infection control for post-grads in all specialties, and the 
incorporation of one-week trainings in antibiotic stewardship and infection control during the 
last three years of medical school, as provided by The Medical Council of India (Ghafur et al. 
2013). 
Vaccination 
Widespread vaccination against common viral and bacterial infections would be a powerful 
measure to reduce both the need for and misuse of antibiotics through indirect and direct 
pathways. Vaccination against major viral pathogens is strongly linked with decreased antibiotic 
use, because a large portion of drug misuse is caused by the unnecessary administration of 
antibiotics for viral infections.  As a result of this correlation, explains one epidemiologist, 
“achieving universal vaccination in developing countries would alone be a huge step forward in 
decreasing disease rates and unnecessary antibiotic use” (Interview 8, 1 December 2015). 
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Vaccines for bacterial pathogens prevent the incidence and spread of infection, establish 
herd immunity in a population, and reduce the need for antimicrobial therapy (Mishra et al. 
2012). Although efforts by the National Immunization Programme have improved Indian 
vaccination rates in recent years, there are currently major gaps in the types of vaccines 
subsidized and there remains a huge inequity in care, with coverage in states ranging from 25 to 
88% (Khera et al. 2011). Even for the vaccines that are labeled as essential and subsidized by the 
government, many rural areas do not have realistic access to care due to social and economic 
factors, such as a lack of knowledge, inaccessibility of transport, or the absence of high-quality 
and proximate medical centers.  
Streptococcus pneumoniae and Haemophilus influenza type B, for example, is a leading 
cause of bacterial pneumonia, meningitis and sepsis in children, is prone to developing drug 
resistance, and affects 43 million under-five children in India every year (Malik and Taneja 2013). 
A very effective vaccine has been developed to protect against most strains of pneumococcal; 
however, “the price makes it inaccessible for most individuals in rural areas” (Conference 3, 30 
November 2015). Attempts to lobby for free or subsidized vaccines against major childhood 
infections such as pneumococcal are necessary to both combat India’s high rates of childhood 
mortality and to conserve the effectiveness of its treatment. According to estimates by the 
Public Health Foundation of India, 11.4 million days of antibiotic consumption in under-five 
children could be avoided annually if universal pneumococcal conjugate vaccination was 
achieved (Laxminarayan, Matsoso, et al. 2015). Additionally, the expansion and improvement of 
programs designed to close the rural coverage gap, such as ASHA health workers who deliver 
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basic healthcare directly to rural villages, or NGOs which facilitate medical transportation and 
provide education, could help obtain universal vaccination (Vashishtha 2012).   
 Innovation: New Antibiotics and Alternative Therapies 
In a 2013 survey of the largest companies, only five new antibiotics were under 
development, none of which were designed with new mechanisms of action, instead treating 
infections by the same increasingly ineffective methods as current antibiotics (Singh 2013). 
Considering the limitations on profit for big pharma, explained one public health worker, 
“government incentives can help encourage companies to continue research and production of 
innovative classes of antibiotics” (Interview 6, 24 November 2015). New antibiotics, of course, 
are a short-term solution, and less cost-efficient than efforts to conserve existing antimicrobials, 
but serve important purposes, as they will buy time before resistance becomes a mass crisis and 
can provide treatment options for those with multi- and pan-resistant infections. The Generating 
Antibiotics Incentives Now (GAIN) Act, a US bill passed in 2012, hopes to give incentives to 
pharmaceutical companies to continue to generate new medicines to fight life-threatening 
resistant infections (Singh 2013). The GAIN Act would make the testing and approval of new 
antibiotics an FDA first-priority and give market-exclusivity to drug companies for five years. 
Similar pushes for Indian pharmaceutical companies could be an important first step, especially, 
explains one researcher, if it was “accompanied by policies to streamline clinical trial and 
approval processes and provide research and development tax credits. Drug development is a 
huge investment and financial risk, anything to ease that risk provides motivation to 
pharmaceutical companies” (Interview 4, 1 December 2015).  
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Non-conventional alternative therapies to antibiotics are promising, long-term solutions. 
Some of these alternative approaches include the administration of antibodies which bind to and 
inactivate pathogens, the use of probiotics as alternative prophylaxis, bacteriophage therapy, or 
viruses which naturally destroy bacteria, immune system stimulation, and lifetime immunity 
bacterial vaccines (Allen et al. 2014). Partnerships between academic researchers and drug 
companies can be formed to get life-saving medicines and alternative therapies on the market 
safer and more efficiently (So et al. 2011). According to one doctor, “there is a lot of great 
scientific research that never makes it to trials or production because of funding constraints.” By 
combining their resources and developing a partnership, public and private sectors can 
overcome market limitations to pursue the development of original new drugs.   
Conclusion 
This project sought to comprehend the human healthcare causes, challenges, and 
solutions of antibiotic resistance in India. The study was conducted over a 25-day period, 
primarily in the cities of New Delhi and Gurgaon in Northern India. Information was collected 
through the use of scientific literature, interviews with doctors and researchers, attendance at 
medical lectures, and observation at several hospitals and the Center for Disease Dynamics, 
Economics, and Policy. Though limited in its scope, the study indicates that the roots of the 
emergence and spread of resistance are a combination of actions by many stakeholders, 
including patients, medical professionals, hospital administrators, pharmacists, and 
pharmaceutical companies. Human healthcare causes of the emergence and spread of antibiotic 
resistance in India include imprudent practices by pharmaceutical companies, insufficient drug 
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regulation and policy enforcement, poor hospital sanitation, unchecked urban drug access and 
correspondingly high rates of patient self-medication, and rampant antimicrobial misuse.  
The future of modern medicine is heavily dependent upon maintaining the effectiveness 
and availability of antimicrobials as a shared and limited resource. The spread of antibiotic 
resistance, therefore, is severe threat to human health security worldwide. India has the 
potential to be a global force for change by tackling AMR head-on with comprehensive 
surveillance and action plans at the national and state level. Considering India’s substantial 
cultural, economic, and political diversity, efforts to address AMR in India must carefully balance 
access, conservation, and innovation. Major obstacles to addressing AMR in India include an 
absence of comprehensive and representative data, a lack of awareness of the issue by both the 
general public and medical community, an overburdened health system fueled by a scarcity of 
resources and qualified staff, health access discrepancies between rural and urban communities, 
attitude and priorities of hospitals and policy makers, disconnect between ideal policy and 
realistic follow-through, and delays in the innovation of diagnostic tools and alternative 
therapies. In order to be effective, strategies for change must be realistic, attentive to contextual 
realities, specifically defined, incentivized for stakeholders, and implemented on as regional a 
level as possible. As misunderstanding and a lack of awareness is the foundation of antibiotic 
misuse, all measures should be instated alongside easily understandable and readily available 
information and explanations. Any policy changes or conservation efforts need to incorporate a 
system of monitoring and feedback by an empowered regulatory body in order to assure 
compliance. Potential routes for combatting AMR include expanded surveillance, promotion of 
education and awareness for medical professionals and the public, antimicrobial stewardship 
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programs, strengthened sanitation and infection control measures in hospitals, and research into 
the development of improved diagnostics and alternative therapies.  
Limitations of the Study 
The scope of this study was limited on the basis of time, resources, and connections. 
First, finding individuals who were both knowledgeable about the topic, and willing to discuss it 
was a considerable challenge. Initially, the researcher intended to gain perspectives on 
antimicrobial resistance from a larger diversity of individuals, including the general public and 
rural health professionals. However, after attempting to question laypeople and non-expert, 
rural physicians, it became clear that this was not a well-known problem in the Indian general 
public and these sessions only produced confusion and misunderstanding on the part of the 
interviewee. Therefore, it was decided that the most prudent course for hearing perspectives on 
AMR would be to talk with experts working to combat this issue, either as a researcher, public 
health worker, or medical professional.  
In addition to the obstacle of finding individuals who had a strong understanding of AMR, 
the researcher also faced difficulty in finding experts who were willing to openly discuss the 
problem. After a 2009 study on the “superbug” New Delhi metallo-β-lactamase 1 (NDM-1) 
created negative media and serious consequences for many involved, antimicrobial resistance 
became a sensitive and somewhat stigmatized topic for many doctors, scientists, and hospital 
workers in India (Yong et al. 2009). There is an inherent margin of error from the fact that the 
researcher could only talk to individuals who already prioritized antibiotic resistance. A hospital 
worker or physician who does not follow stringent policies regarding infection control and 
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prudence when prescribing antibiotics, for example, is unlikely to consent to having a student 
researching AMR observe or interview them.  
Additional limitations were mostly due to practical restraints of time and travel. The 
research period was less than four weeks, and therefore restricted in the amount of field work 
that could be conducted. Without access to a lab or scientific testing equipment, the researcher 
was unable to perform any original scientific field work first hand, and therefore had to heavily 
rely on peer-reviewed journal articles for data on resistance and infections. Additionally, 
although some observation and cited studies took place in more rural hospitals, this study is 
mostly skewed toward urban areas because of restraints in travel and accommodation.  
Suggestions for  Future Research 
 Interesting topics for future ISP health research may include the following. First, looking 
at perceptions and perspectives of pharmacists in India on antibiotic resistance and how they 
affect antibiotic dispersal rates. Second, obtaining qualitative data on the knowledge and 
awareness of antibiotic resistance by rural doctors or the general public in India. Third, an 
examination of pilot antimicrobial stewardship and infection control programs in government-
funded or rural hospitals. Finally, a study comparing the effectiveness and outcomes of different 
methods for educating medical professionals and laypeople about antibiotic resistance would be 
useful for future health education campaigns.  
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